Ikumi Kuriwaki

This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Astellas Pharma Gmbh, Cytokinetics, Inc., Kotobuki Pharmaceutical Co Ltd. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ikumi Kuriwaki. Retrieved from https://idiyas.com/inventor/ikumi-kuriwaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 75.0

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 10.3

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

Kotobuki Pharmaceutical Co Ltd

Tenvie Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741942 - Substituted pyridazine compound (2026-09-22),

2. 12729206 - 4-aminoquinazoline compound (2026-09-08),

3. 12441691 - Bicyclic 1,4-diazepanones and therapeutic uses thereof (2025-10-14),

4. 11981644 - Bicyclic 1,4-diazepanones and therapeutic uses thereof (2024-05-14),

5. 11912679 - Aryl alkynamide derivatives (2024-02-27),

6. 9464077 - Nitrogen-containing aromatic heterocyclic compound (2016-10-11),

7. 9399038 - Benzothiophene compound (2016-07-26),

8. 8981119 - Benzothiophene compound (2015-03-17),

Title: Ikumi Kuriwaki: Innovator in Pharmaceutical Chemistry

Introduction

Ikumi Kuriwaki is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of six patents to her name, Kuriwaki's work is recognized for its potential impact on treating various diseases.

Latest Patents

Among her latest patents is the invention of bicyclic 1,4-diazepanones and their therapeutic uses. This patent provides compounds of a specific formula, including stereoisomers and pharmaceutically acceptable salts. The invention outlines methods for using these compounds to treat diseases and conditions that respond to the modulation of skeletal sarcomere contractility. This innovative approach highlights Kuriwaki's commitment to advancing medical science through her research.

Career Highlights

Kuriwaki has worked with notable companies in the pharmaceutical industry, including Astellas Pharma GmbH and Cytokinetics, Inc. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout her career, Kuriwaki has collaborated with esteemed colleagues such as Hiroyuki Hisamichi and Bradley Paul Morgan. These partnerships have fostered an environment of innovation and have led to the successful development of her patented compounds.

Conclusion

Ikumi Kuriwaki's contributions to pharmaceutical chemistry exemplify her dedication to innovation and research. Her patents and collaborations reflect her significant role in advancing therapeutic solutions for various medical conditions.

Profile summary based on public USPTO records.